The clinical value of measuring antiphospholipid antibodies in high risk primigravidae and nullipara, a case control study
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20175227Keywords:
Antiphospholipid, Nullipara, PrimigravidaeAbstract
Background: Antiphospholipid syndrome (APS) is an autoimmune thrombophilic condition that is marked by the presence in blood of antibodies that recognize and attack phospholipid-binding proteins, rather than phospholipid itself. The clinical manifestations of APS include vascular thrombosis and pregnancy complications, especially recurrent spontaneous miscarriages and, less frequently maternal thrombosis. Obstetric manifestations of APS are not restricted to fetal loss. Current APS criteria include preterm labour, oligohydramnios, neonatal complications as prematurity-estimated at 30-60% and more common in SLE patients, intrauterine growth restriction “IUGR”, fetal distress and rarely fetal or neonatal thrombosis, associated maternal obstetric complications as pre-eclampsia/eclampsia and HELLP syndrome, arterial or venous thrombosis and other aPL-related complications as placental insufficiency.
Methods: The study included 90 primigravida and nullipara during their first trimester antenatal care visits, divided into 2 groups after signing a well-informed consent to declare their willing to participate in the study. All selected cases and control group were subjected to demographic data, thorough history taking, clinical examination focused on arterial blood pressure, body mass index, laboratory investigations fasting and random blood glucose level, serum analysis of anti-phospholipid anti bodies by enzyme linked immunosorbent assay (ELISA) including anticardiolipin antibodies (ACL), anti β2-glycoprotein I antibodies (Anti β2 GPI) and citrated sample for lupus anticoagulant test (LA).
Results: We can conclude from the current study that aPLs namely lupus anticoagulant is significantly more common in high risk primigravidae having obesity, hypertension and diabetes mellitus than those without risk factors.
Conclusions: aPLs antibodies as lupus anticoagulant is significantly more common in high risk primigravidae having obesity, hypertension and diabetes mellitus than those without risk factors.
References
Negrini S, Pappalardo F, Murdaca G, Indiveri F, Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. Clinical and Experimental Medicine. 2017;17(3):257-67.
Cabrera CDM, Rodriguez-Jaimes C, Acevedo-Gallegos S, Gallardo-Gaona JM, Velazquez-Torres B, Ramirez-Calvo JA. Controversies concerning the antiphospholipid syndrome in obstetrics. Reumatologia clinica. 2017;13(1):30-6.
Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. New Eng J Med. 2002;346(10):752-63.
de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thrombosis Haemostasis. 2005;3(9):1993-7.
Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheumatism. 2009;61(1):29-36.
Bremme KA. Haemostatic changes in pregnancy. Best Practice Res Clin Haematol. 2003;16(2):153-68.
Pierangeli SS, Favaloro EJ, Lakos G, Meroni PL, Tincani A, Wong RC, et al. Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL task force at the 13th International Congress on Antiphospholipid Antibodies. Int J Clin Chem. 2012;413(1-2):358-60.
Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. J Thrombosis Haemostasis. 2009;7(10):1737-40.
Boddi M, Prisco D, Fedi S, Cellai AP, Liotta AA, Parretti E, et al. Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes. Thrombosis Res. 1996;82(3):207-16.
Rollino C, Boero R, Elia F, Montaruli B, Massara C, Beltrame G, et al. Antiphospholipid antibodies and hypertension. Lupus. 2004;13(10):769-72.
Loukidi B, Merzouk H, Merzouk SA, Malti N, Taouli K, Belarbi B, et al. Thrombosis factors and oxidant/antioxidant markers in obese and hypertensive women during pregnancy. Blood Pressure. 2015;24(4):242-9.
Gary T, Belaj K, Bruckenberger R, Hackl G, Hafner F, Froehlich H, et al. Primary antiphospholipid antibody syndrome-one further aspect of thrombophilia in overweight and obese patients with venous thromboembolism. Obesity (Silver Spring, Md). 2013;21(9):E463-6.
Moffat K, Raby A, Crowther M. Lupus anticoagulant testing. Methods in molecular biology (Clifton, NJ). 2013;992:97-108.
Borges RB, Bodanese LC, Muhlen CA, Repetto G, Viehe M, Norman GL, et al. Anti-beta2-glycoprotein I autoantibodies and metabolic syndrome. Brazilian Cardiol Arch. 2011;96(4):272-6.
Valdes-Macho E, Cabiedes J, Villa AR, Cabral AR, Alarcon-Segovia D. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. Arch Med Res. 2002;33(5):460-5.
Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thrombosis Haemostasis. 2016;14(4):675-84.
Rezk M, Dawood R, Badr H. Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study. J Maternal-Fetal Neonatal Med. 2016;29(24):4015-9.
